HC Wainwright Expects Stronger Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – HC Wainwright upped their FY2026 earnings estimates for shares of Krystal Biotech in a research note issued on Monday, April 28th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $6.30 per share for the year, up from their prior forecast of $6.23. HC Wainwright currently has a “Buy” rating and a $240.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech’s FY2027 earnings at $8.56 EPS and FY2028 earnings at $9.85 EPS.

A number of other equities analysts also recently commented on the company. Citigroup raised their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. Chardan Capital boosted their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $222.71.

Krystal Biotech Trading Down 2.5 %

Shares of Krystal Biotech stock opened at $165.69 on Thursday. The business’s fifty day moving average price is $175.22 and its 200 day moving average price is $171.38. Krystal Biotech has a twelve month low of $141.72 and a twelve month high of $219.34. The stock has a market capitalization of $4.79 billion, a P/E ratio of 55.41 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter last year, the firm posted $0.30 earnings per share. Krystal Biotech’s revenue was up 116.4% on a year-over-year basis.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 13.70% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech during the 3rd quarter valued at approximately $40,000. Franklin Resources Inc. raised its holdings in Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares in the last quarter. Avanza Fonder AB acquired a new stake in Krystal Biotech in the fourth quarter valued at $119,000. Crossmark Global Holdings Inc. boosted its stake in Krystal Biotech by 5.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after acquiring an additional 121 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its holdings in Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock worth $8,239,000 after acquiring an additional 15,545 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).